A detailed history of Price T Rowe Associates Inc transactions in Arvinas, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,853,716 shares of ARVN stock, worth $72.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,853,716
Previous 3,988,869 3.39%
Holding current value
$72.2 Million
Previous $106 Million 10.61%
% of portfolio
0.01%
Previous 0.01%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$23.66 - $32.73 $3.2 Million - $4.42 Million
-135,153 Reduced 3.39%
3,853,716 $94.9 Million
Q2 2024

Aug 14, 2024

SELL
$24.46 - $40.4 $9.28 Million - $15.3 Million
-379,549 Reduced 8.69%
3,988,869 $106 Million
Q1 2024

May 15, 2024

BUY
$36.38 - $52.31 $19.5 Million - $28.1 Million
536,295 Added 13.99%
4,368,418 $180 Million
Q4 2023

Feb 14, 2024

BUY
$14.19 - $42.33 $16.2 Million - $48.4 Million
1,143,452 Added 42.53%
3,832,123 $158 Million
Q3 2023

Nov 14, 2023

SELL
$19.64 - $28.21 $105,368 - $151,346
-5,365 Reduced 0.2%
2,688,671 $52.8 Million
Q2 2023

Aug 14, 2023

BUY
$21.73 - $31.43 $3.92 Million - $5.67 Million
180,318 Added 7.17%
2,694,036 $66.9 Million
Q1 2023

May 15, 2023

BUY
$26.15 - $37.26 $3.81 Million - $5.42 Million
145,588 Added 6.15%
2,513,718 $68.7 Million
Q4 2022

Feb 14, 2023

BUY
$32.47 - $57.24 $6.12 Million - $10.8 Million
188,362 Added 8.64%
2,368,130 $81 Million
Q3 2022

Nov 14, 2022

SELL
$41.87 - $57.99 $45.5 Million - $63.1 Million
-1,087,802 Reduced 33.29%
2,179,768 $97 Million
Q2 2022

Aug 15, 2022

BUY
$36.01 - $74.24 $5.79 Million - $11.9 Million
160,860 Added 5.18%
3,267,570 $138 Million
Q1 2022

May 16, 2022

BUY
$60.27 - $81.57 $11.8 Million - $16 Million
196,104 Added 6.74%
3,106,710 $209 Million
Q4 2021

Feb 14, 2022

BUY
$65.85 - $96.21 $23.3 Million - $34 Million
353,452 Added 13.82%
2,910,606 $239 Million
Q3 2021

Nov 15, 2021

BUY
$73.2 - $107.87 $5.66 Million - $8.35 Million
77,385 Added 3.12%
2,557,154 $210 Million
Q2 2021

Aug 16, 2021

BUY
$60.45 - $84.26 $5.64 Million - $7.86 Million
93,314 Added 3.91%
2,479,769 $191 Million
Q1 2021

May 17, 2021

BUY
$58.19 - $91.37 $8.21 Million - $12.9 Million
141,006 Added 6.28%
2,386,455 $158 Million
Q4 2020

Feb 16, 2021

BUY
$20.19 - $84.93 $45.3 Million - $191 Million
2,245,449 New
2,245,449 $191 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $997M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.